Analyst Rating Update on Mylan N.V. (MYL)

Mylan N.V. (MYL) : The consensus on Mylan N.V. (MYL) based on 10 analyst recommendation on the company stock is 2, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 2 which endorses a Buy on the stock. However, 5 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 5 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Mylan N.V. (MYL) : 7 investment research analysts covering Mylan N.V. (MYL) have an average price target of $59.14 for the near short term. The highest target price given by the Brokerage Firm to the stock is $71 and the lowest target is $51 for the short term. Analysts expect the variance to be within $7.47 of the average price.

For the current week, the company shares have a recommendation consensus of Buy. Also, Major Brokerage house, Leerink Swann maintains its ratings on Mylan N.V. (NASDAQ:MYL). In the latest research report, Leerink Swann lowers the target price from $53 per share to $51 per share. According to the latest information available, the shares are now rated Outperform by the analysts at the agency. The rating by the firm was issued on May 4, 2016.


Mylan N.V. (NASDAQ:MYL): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $46.33 and $46.30 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $48.54. The buying momentum continued till the end and the stock did not give up its gains. It closed at $48.41, notching a gain of 4.04% for the day. The total traded volume was 7,782,505 . The stock had closed at $46.53 on the previous day.

Mylan N.V., formerly Mylan Inc., is a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty. The Companys generic pharmaceutical business is conducted primarily in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA); and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its specialty pharmaceutical business is conducted by Mylan Specialty L.P. (Mylan Specialty). The Companys API business is conducted through Mylan Laboratories Limited (Mylan India), which is included within the Asia Pacific region in its Generics Segment. Mylan provides products to customers in approximately 140 countries and territories.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.